Practical Interpretation of 18F PSMA PET/CT: Spectrum of Findings

Abstract

Prostate cancer imaging has evolved significantly with the introduction of 18 F DCFPyL positron emission tomography/computed tomography (PET/CT), a novel radiotracer targeting the prostate-specific membrane antigen (PSMA). This promising imaging modality has demonstrated superior sensitivity and specificity for detecting local, regional, and distant recurrences compared with conventional imaging modalities. This article aims to provide a comprehensive overview of the practical interpretation of 18 F DCFPyL PET/CT in the management of prostate cancer, including its advantages, potential pitfalls, and comparison to other imaging techniques. Through a better understanding of 18 F DCFPyL PET/CT, clinicians can more effectively incorporate this advanced imaging tool into routine clinical practice, ultimately optimizing prostate cancer diagnosis, staging, and management.